- Home
- IMCR
as 12-17-2024 4:00pm EST
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
| Founded: | 2008 | Country: | United Kingdom |
| Employees: | N/A | City: | OXFORDSHIRE |
| Market Cap: | 1.7B | IPO Year: | 2021 |
| Target Price: | $65.18 | AVG Volume (30 days): | 246.4K |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $28.17 - $76.98 | Next Earning Date: | 11-06-2024 |
| Revenue: | $296,312,000 | Revenue Growth: | 25.09% |
| Revenue Growth (this year): | 29.19% | Revenue Growth (next year): | 12.56% |
Latest Immunocore Holdings plc News
IMCR Breaking Stock News: Dive into IMCR Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
Benzinga
5 days ago
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
MT Newswires
5 days ago
Morgan Stanley Downgrades Immunocore Holdings to Equalweight From Overweight, Cuts Price Target to $35 From $74
Zacks
6 days ago
All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy
TipRanks
6 days ago
Immunocore, EORTC announce enrollment of first patient in Phase 3 ATOM trial
MT Newswires
7 days ago
Immunocore Enrolls First Patient in Phase 3 Uveal Melanoma Trial
GlobeNewswire
7 days ago
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
MT Newswires
15 days ago
Immunocore Says UK NICE Recommends Kimmtrak for Funding Through National Health Service in England
Compare IMCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMCR Immunocore Holdings plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.